PTC Therapeutics, Inc. (PTCT)

Over the last 12 months, PTC Therapeutics' stock price has risen by 59.80%. Recent stock events include analyst coverage with positive ratings and price targets following Sephience's launch, the announcement of Q4 and full-year 2025 financial results exceeding guidance, the withdrawal of the Translarna NDA resubmission after FDA feedback, the sale of Evrysdi royalty to Royalty Pharma for $240 million upfront and up to $60 million in sales-based milestones, and an End-of-Phase 2 meeting with the FDA regarding the votoplam Huntington's disease program, with alignment reached on the design of a global Phase 3 trial.

Specific demand seasonality for PTC Therapeutics' products was not explicitly found. Demand for its treatments is likely driven more by disease incidence and diagnosis rather than seasonal fluctuations.

PTC Therapeutics, Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders, operating within the biotechnology sector and pharmaceutical preparation manufacturing industry. The company addresses unmet medical needs by targeting the genetic causes of rare diseases through small molecule drugs and gene therapy, integrating innovative research with a global commercial infrastructure. Key products include Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza for aromatic L-amino acid decarboxylase deficiency, Sephience for phenylketonuria, and Evrysdi for spinal muscular atrophy (for which PTC receives royalties). Pipeline products include vatiquinone for Friedreich's ataxia and PTC518 for Huntington's disease.

PTC Therapeutics is headquartered in Warren, New Jersey, U.S., and operates globally. Sephience has been launched globally, with approvals in Japan in December 2025 and Brazil in February 2026, and its global footprint is expected to expand to 20 to 30 countries by the end of 2026.

PTC Therapeutics has maintained a positive brand reputation, earning Gallup's Exceptional Workplace Award for the fifth consecutive year in 2026. The company actively participates in initiatives like Women's History Month and Rare Disease Day, emphasizing a patient-centric approach.

PTC Therapeutics' stock is primarily held by institutional investors, including BlackRock Inc., Vanguard Group Inc., and RTW Investments LP. Michael Schmertzler is the largest individual shareholder, owning 4.60% of the company. There has been significant insider selling over the past three months.